Core Insights - OSE Immunotherapeutics has announced a strategic realignment of its R&D portfolio, pausing the development of OSE-230 to focus on late-stage assets lusvertikimab (OSE-127) and Tedopi®, which are expected to generate multiple clinical catalysts from 2026 to 2028 [1][3][9] Group 1: Portfolio Realignment - The decision to pause OSE-230 reflects a disciplined evolution of the company's portfolio, concentrating resources on high-potential late-stage programs [3][4] - The company aims to enhance its ability to deliver late-stage clinical progress and secure meaningful partnerships by focusing on its cornerstone assets [3][9] Group 2: Discontinuation of Other Programs - Boehringer Ingelheim has discontinued the development of BI 770371 for MASH after a Phase 2 study showed no efficacy, although the treatment was well tolerated [2][5] - OSE Immunotherapeutics will also discontinue exploratory research on the CLEC-1 program in oncology, aligning its portfolio with late-stage value creation strategies [7][9] Group 3: Expected Clinical Catalysts - OSE Immunotherapeutics has identified chronic pouchitis and hidradenitis suppurativa as new indications for lusvertikimab, with a subcutaneous formulation being developed for ulcerative colitis [8][14] - The company is set to complete the Phase 3 trial for Tedopi® in NSCLC, with multiple key read-outs expected between 2026 and 2028 [14]

Core Viewpoint - Genmab A/S has decided to discontinue the clinical development of acasunlimab to focus on higher-value opportunities in its late-stage pipeline, despite encouraging clinical data observed to date [1][2][7]. Group 1: Decision and Strategic Focus - The decision to halt the acasunlimab program is part of Genmab's strategic focus on maximizing value in its late-stage portfolio [1][7]. - Genmab will redirect resources towards programs with higher potential impact, specifically EPKINLY (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina-S), which are currently in late-stage development [1][2]. Group 2: Financial Guidance - This decision will not affect Genmab's full-year 2025 financial guidance, indicating stability in the company's financial outlook despite the program discontinuation [3][7]. Group 3: Company Background - Genmab is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases, with over 25 years of experience in advancing various antibody-based therapeutic formats [4][5]. - The company has a strong late-stage clinical pipeline and aims to deliver transformative medicines to patients [4].